
Opinion|Videos|July 3, 2024
Investigational Therapies Paving New PNH Treatment Pathways
Dr Haumschild continues leading a discussion surrounding potential treatment advancements in the PNH landscape.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Looking towards the future, what advancements do you anticipate in the treatment landscape for PNH and other complement-driven rare diseases, particularly in relation to investigational therapeutics targeting the alternative pathway?
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Panel Backs 6 Peptides for Compounding
2
FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer
3
Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD
4
Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%
5





